Announced Sat, 8 Aug · 11:34 IST
AstraZeneca India gets CDSCO nod for Enhertu additional indication
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.2%1-day move
₹8200.00
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-3.2-3.7-5.1-5.7-6.7-8.5————
Up moveDown movePending
AI summary
AstraZeneca Pharma India received CDSCO approval to import and market Trastuzumab Deruxtecan (Enhertu) for an additional indication: adjuvant treatment of HER2-positive breast cancer patients with residual invasive disease after neoadjuvant therapy. The drug was already approved for other indications; this expands its use in India subject to any further statutory approvals.
Likely market impact
Positive - broader label for Enhertu opens a larger HER2-positive breast cancer market in India, supporting future revenue growth.